multi-center Phase II prognostic study of chronic lymphocytic leukemia ( CLL ) . intended to stratify indolent ( simmering ) versus aggressive disease. focus area for GeneGo this year , " said Julie Bryant , VP business development. pharmaceutical companies , including Bayer , Merck , Organon and Roche .